BioArctic AB (BIOA_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to BioArctic Q2 Report 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Gunala Oswald and CFO Anders Martinloff. Please go ahead. Thank you. Good morning and welcome to BioArctic's presentation for the second quarter of 2025. Bioartic is now entering a new era. It's an era of profitable growth and I think it's signified by yet another strong quarter and a lot of activities throughout the different parts of the business. We see increasing Lecambi royalties and we are very pleased with the new partnership with Novartis. It's the third partnership utilizing our brain-transporter technology, and it's the first of its kind. And I'll talk more about that in today's presentation. Next slide, please. Biotic is listed at Nasdaq Stockholm large cap, and this is our disclaimer. Next slide, please. I'm Gunilla Asvold, and I'm the CEO of Biotic. And today, I will share the presentation with our CFO, Anders Martin Lööf, and also with our Chief R&D Officer, Johanna Felting, and our chief commercial officer, Anna-Kaja Grönblad. Next slide, please. I will start our presentation, and I will be giving some key highlights. Next slide, please. But before I do that, I just want to do a high-level introduction to Bioartic, if we have any new listeners today. Bioartic is among world-leading innovators in precision neurology. We have two different platforms. The first one is innovation and generation and development of highly selective antibodies that are targeting aggregated, misfolded forms of toxic proteins like leucanumab or leucanbin and exudanumab. The second pa...